Halozyme Therapeutics (HALO) Competitors $46.96 -0.36 (-0.76%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends HALO vs. BIIB, UTHR, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, MDGL, and IONSShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Ionis Pharmaceuticals Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations. Does the MarketBeat Community favor HALO or BIIB? Biogen received 1285 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.76% of users gave Biogen an outperform vote while only 69.51% of users gave Halozyme Therapeutics an outperform vote. CompanyUnderperformOutperformHalozyme TherapeuticsOutperform Votes52269.51% Underperform Votes22930.49% BiogenOutperform Votes180771.76% Underperform Votes71128.24% Is HALO or BIIB more profitable? Halozyme Therapeutics has a net margin of 41.43% compared to Biogen's net margin of 16.81%. Halozyme Therapeutics' return on equity of 179.82% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Halozyme Therapeutics41.43% 179.82% 23.56% Biogen 16.81%14.98%8.59% Do analysts rate HALO or BIIB? Halozyme Therapeutics currently has a consensus target price of $61.11, indicating a potential upside of 30.13%. Biogen has a consensus target price of $242.68, indicating a potential upside of 65.69%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Halozyme Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Biogen 0 Sell rating(s) 16 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.45 Does the media favor HALO or BIIB? In the previous week, Biogen had 6 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 17 mentions for Biogen and 11 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.15 beat Biogen's score of 0.12 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in HALO or BIIB? 97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.4% of Halozyme Therapeutics shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, HALO or BIIB? Halozyme Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Biogen has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Which has preferable valuation and earnings, HALO or BIIB? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHalozyme Therapeutics$947.36M6.31$281.59M$3.0215.55Biogen$9.61B2.22$1.16B$11.0713.23 SummaryHalozyme Therapeutics beats Biogen on 10 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.97B$2.94B$5.10B$9.07BDividend YieldN/A1.90%4.90%4.21%P/E Ratio15.5545.9491.0817.15Price / Sales6.31411.851,113.51116.81Price / Cash14.91182.1042.2637.86Price / Book74.543.894.784.78Net Income$281.59M-$42.21M$119.77M$225.60M7 Day Performance-2.17%-2.14%-1.87%-1.23%1 Month Performance2.76%4.21%11.46%3.07%1 Year Performance27.33%18.39%30.53%16.48% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.9948 of 5 stars$46.96-0.8%$61.11+30.1%+29.1%$5.97B$947.36M15.55390Analyst ForecastPositive NewsHigh Trading VolumeBIIBBiogen4.6302 of 5 stars$150.99+0.6%$245.32+62.5%-41.0%$22.00B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7129 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8286 of 5 stars$134.40+6.1%$165.00+22.8%+12.6%$13.61B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7054 of 5 stars$70.38+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9845 of 5 stars$65.89-0.2%$94.20+43.0%-29.1%$12.56B$2.75B39.533,401Positive NewsEXASExact Sciences4.4914 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600EXELExelixis4.5106 of 5 stars$36.02+2.8%$31.47-12.6%+43.4%$10.29B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.101 of 5 stars$160.24+2.4%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.239 of 5 stars$309.23+1.6%$347.33+12.3%+39.5%$6.74BN/A-12.1490Positive NewsIONSIonis Pharmaceuticals4.4164 of 5 stars$38.46+5.1%$60.65+57.7%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors NBIX Competitors INCY Competitors BMRN Competitors EXAS Competitors EXEL Competitors RGEN Competitors MDGL Competitors IONS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HALO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HALO Stock Alerts